TRIS PHARMA Overview
Upcoming Projects (TRIS PHARMA)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (TRIS PHARMA)
-
Discussing Tris Pharma's Phase 3 results for Alleviate-2, an investigational oral dual-NMR agonist, for the treatment of moderate-to-severe acute pain following bunionectomy surgery.
Ticker: TRIS PHARMA
Executed On: Mar 20, 2025 at 07:00 PM EDT -
A Fourth Opinion: Discussing the data to date on cebranopadol, an Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain
Tickers: TRIS PHARMA, VRTX
Executed On: Mar 11, 2025 at 10:00 AM EDT -
A Third Opinion: Discussing the data to date on cebranopadol, an Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain
Tickers: TRIS PHARMA, VRTX
Executed On: Mar 05, 2025 at 02:30 PM EST -
A Second Opinion: Discussing the data to date on cebranopadol, an Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain
Tickers: TRIS PHARMA, VRTX
Executed On: Mar 05, 2025 at 02:00 PM EST -
Discussing the data to date on cebranopadol, an Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain
Tickers: TRIS PHARMA, VRTX
Executed On: Feb 21, 2025 at 02:00 PM EST
Upcoming & Overdue Catalysts (TRIS PHARMA)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (TRIS PHARMA)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
